03C0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of :

William Scott : Group Art Unit: NOT YET ASSIGNED

Serial No.: 09/640,780 :

Filed: August 18, 2000 : Examiner: NOT YET ASSIGNED

For: INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The attached PTO Form-1449 lists references cited in the ancestor application of the above-identified application. In accordance with 37 C.F.R. §1.98(d), copies of these documents are not enclosed. The Examiner is respectfully requested to acknowledge consideration of the listed references by initialing the attached Form PTO 1449 indicating that the information has been considered and made of record herein.

This Information Disclosure Statement is being submitted prior to receipt of the first action on the merits. Therefore, it is believed that no fee is required. See 37 C.F.R. §1.97(b)(3).

Respectfully submitted,

Richard J. Traverso (Reg. No. 30,595)
Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Boulevard, Suite 1400
Arlington, VA 22201
(703) 812-5310
Internet Address: traverso@mwzb.com

Filed: **October 18, 2000**

RJT/lvb
K:\PAT\Bayer\8c1\prior refs.wpd

BAYER 8 C1

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DKT. NO.	SERIAL NO.
	BAYER 8-C1	09/640,780
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT	
	William Scott	
(Use several sheets if necessary)	FILING DATE	GROUP
	August 18, 2000	NOT YET ASSIGNED

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date
	AA	3,823,161	07/09/74	Lesser			
	AB	5,130,331	07/14/92	Pascual			
	AC	4,808,588	02/28/89	King			
	AD	3,424,760	01/28/69	Helsley et al.			
	AE	3,424,761	01/28/69	Helsley et al.			
	AF	3,424,762	01/28/69	Helsley et al.			
	AG	4,071,524	01/31/78	Banitt			
	AH	4,111,683	09/05/78	Singer			
	AI	4,437,878	03/20/78	Acker et al.			
	AJ	4,643,849	02/17/87	Hirai et al.			
	AK	5,773,459	06/30/98	Tang et al.			
	AL	5,508,288	04/16/96	Forbes et al.			
	AM	4,062,861	12/13/77	Yukinaga et al.			
	AN	4,111,680	09/05/78	Yukinaga et al.			
	AO	4,116,671	09/26/78	Yukinaga et al.			
	AP	4,212,981	07/15/80	Yukinaga et al.			
	AQ	5,162,360	11/10/92	Creswell et al.			
	AR	4,514,571	04/30/85	Nakai et al.			
	AS	3,754,887	08/28/73	Brantley			
	AT	3,646,059	02/29/72	Brantley			
	AU	5,696,138	12/9/97	Olesen et al.			
	AV	5,780,483	7/14/98	Widdowson et al.			
	AW	4,405,644	9/20/83	Kabbe et al.			
	AX	4,473,579	9/25/84	Devries et al.			
	AY	4,526,997	7/2/85	O'Doherty et al.			
	AZ	4,468,380	8/28/84	O'Doherty et al.			
	BA	4,623,662	11/18/86	De Vries			
	BB	4,985,449	1/15/91	Haga et al.			
	BC	5,312,820	5/17/94	Ashton et al.			
	BD	4,410,697	10/18/83	Török et al.			
	BE	4,001,256	1/4/97	Callahan et al.			
	BF	5,399,566	3/21/95	Katano et al.			
	BG	5,500,424	3/19/96	Nagamine et al.			
	BH	5,597,719	1/28/97	Freed et al.			

	BI	4,183,854	1/80	Crossley			
	BJ	3,828,001	8/74	Broad et al.			
	BK	4,740,520	4/88	Hallenbach et al.			
	BL	5,319,099	6/7/94	Kamata et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	BM	EP 335156	03/11/89	European				X
	BN	EP 459887	05/28/91	European				X
	BO	EP 371876	11/28/89	European				X
	BP	93/24458	12/9/93	WO			X	
	BQ	2,146,707	10/12/95	Canada			X	
	BR	96/40673	12/19/96	WO			X	
	BS	94/14801	07/07/94	WO			X	
	BT	94/25012	11/10/94	WO			X	
	BU	1,590,870	06/10/81	England			X	
	BV	93/18028	09/16/93	WO			X	
	BW	94/18170	08/18/94	WO			X	
	BX	DE 3305866 A1	02/19/83	Germany				X
	BY	95/02591	01/26/95	WO			X	
	BZ	95/13067	05/18/95	WO			X	
	CA	95/07922	03/23/95	WO			X	
	CB	95/31451	11/23/95	WO			X	
	CC	A1 96/40675	12/19/96	WO			X	
	CD	JP 53 086033	7/29/98	Japan				
	CE	JP 51 063170	6/1/76	Japan				
	CF	97/49400	12/31/97	WO				
	CG	97/49399	12/31/97	WO				
	CH	96/40673	12/19/96	WO				
	CI	99/00357	1/7/99	WO				
	CJ	97/45400	12/4/97	WO				
	CK	96/02112	3/8/90	WO				
	CL	99/00370	1/7/99	WO				
	CM	97/29743	8/21/97	WO				
	CN	98/22432	5/28/98	WO				
	CO	96/25157 A1	8/22/96	WO				
	CP	97/40028 A1	10/30/97	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	CQ	Dumas, J., "CAS Substructure," May 6, 1997, pages 1-29.

	CR	Scott, Bill, "Substructure (Patent Families)," August 11, 1997, pages 1-19.
	CS	Scott, Bill, "Substructure #2," November 25, 1997, pages 1-3.
	CT	"Beilstein number" Collection, 28 pages.
	CU	"Beilstein Collection," 4 pages.
	CV	Scott, Bill, "Substructure Search," December 2, 1997, pages 1-51.
	CX	Substructure Search, pages 1-30.
	CY	Derwent World Patents Index Search, pages 20-26.
	CZ	Abstract of EP 116,932
	DA	Abstract of EP 676,395
	DB	Abstract of EP 202,538
	DC	Abstract of EP 16,371
	DD	Avruch et al., "Raf meets Ras: completing the framework of a signal transduction pathway", TIBS 19; July 1994; pp. 279-2823.
	DE	White, A. D., et al., "Heterocyclic Ureas: Inhibitors of Acyl-CoA:Cholesterol *O*-Acyltransferase as Hypocholesterolemic Agents," June 6, 1996, pages 4382-95.
	DF	Audia, James E., et al., "Potent, Selective Tetraphdro-ß-carboline Antagonists of the Serotonin 2B ($5HT_{2B}$) Contractile Receptor in the Rat Stomach Fundus," January 22, 1996, pages 2773-80.
	DG	Forbes, Ian T., "N-(1-Methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: A Novel, High-Affinity 5-HT_{2B} Receptor Antagonist," March 17, 1995, pages 855-57.
	DH	Boulton, A. J., et al., "Heterocyclic Rearrangements. Part X.[1] A Generalised Monocyclic Rearrangement," 1967, 2005-07.
	DI	N. S. Magnuson, et al., "The Raf-1 serine/threonine protein kinase," Cancer Biology, vol. 5, 1994, pages 247-253.
	DJ	G. Daum, et al., The ins and outs of Raf Kinases,:" TIBS 19, November 1994, pages 474-80.
	DK	W. Kolch, et al., "Raf-1 protein kinase is required for growth of induced NIH/3T3 cells," Letters to Nature, vol. 349, January 31, 1991, page 226-28.
	DL	M. Fridman, et al., "The Minimal Fragments of c-Raf-1 and NF1 That Can Suppress v-Ha-Ras-Induced Malignant Phenotype," The Journal of Biological Chemistry, vol. 269, no. 48, December 2, 1994, pages 30105-108.
	DM	G. L. Bolton, et al., Chapter 17. Ras Oncogene Directed Approaches in Cancer Chemotherapy, Annual Reports In Medicinal Chemistry, vol. 29, 1994, pages 165-74.
	DN	J. L. Bos, "ras Oncogenes in Human Cancer: A Review," Cancer Research, vol. 49, September 1, 1989, pages 4682-89.
	DO	Michaelis, Justus, Liebigs Ann. Chem. (JLACBF) 397, 1913, 143.
	DP	B. P. Monia, et al., "Antitumor activity of a phosphorothioate antisense oligodeopxynucleotide targeted against C-raf kinase," Nature Medicine, vol. 2, No. 6, June 1996, pages 668-75.
	DQ	Lee, et al., Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhiibitors," N.Y. Academy of Science, 1993, pages 149-70.
	DR	F. Lepage, et al., "New N-aryl isoxazolecarboxamides and N-isoxazolybenzamides as anticonvulsant agents," Eur. J. Med. Chem, vol. 27, 1992, pages 581-93.
	DS	Ridley, et al., "Actions of IL-1 are Selectively Controlled by p38 Mitogen-Activated Protein Kinase," The American Association of Immunologists, 1997, page 3165-73.
	DT	Chemical Abstract, Vol. 116, No. 21, 25 May 1992, pages 741-742.

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date
	DU	5,059,614	10/22/91	Lepage et al.			
	DV	3,743,498	07/03/73	Brantley			
	DW	3,547,940	12/15/70	Brantley			
	DX	5,432,468	7/11/95	Moriyama et al.			
	DY	1,742,156	2/31	Fitzky			
	DZ	2,046,375	07/36	Goldstein et al.			
	EA	2,093,265	9/36	Coffby et al.			
	EB	2,288,422	6/42	Rohm			
	EC	2,683,082	7/54	Hill et al.			
	ED	2,745,874	5/56	Schetty et al.			
	EF	2,781,330	2/57	Downey			
	EG	2,867,659	1/59	Model et al.			
	EH	2,877,268	3/59	Applegate et al.			
	EI	2,960,488	11/60	Tamblyn et al.			
	EJ	3,689,550	9/72	Schellenbaum et al.			
	EK	3,860,645	1/95	Nikawitz			
	EL	5,423,905	6/95	Fringeli			
	EM	2,973,386	2/61	Weldon			
	EN	3,230,141	1/66	Frick et al.			
	EO	4,863,924	9/89	Haga et al.			
	EP	4,511,571	4/85	Böger et al.			
	EQ	4,173,638	11/79	Nishiyama et al.			
	ER	4,173,637	11/79	Nishiyama et al.			
	ES	4,820,871	4/89	Kissener et al.			
	ET	4,983,605	1/91	Kondo et al.			
	EU	5,098,907	3/92	Kondo et al.			
	EV	5,036,072	7/91	Nakajama et al.			
	EW	5,470,882	11/95	Dixon et al.			
	EX	5,429,918	7/95	Seto et al.			
	EY	3,151,023	9/64	Martin			
	EZ	3,200,035	8/65	Martin et al.			
	FA	5,807,891	9/98	Bold et al.			
	FB	4,009,847	3/1/77	Aldrich et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	FC	95/33458	12/95	WO				
	FD	0 771 333	3/57	Great Britain				
	FE	0 921 682	3/63	Great Britain				
	FF	0 253 997	2/88	East Germany				
	FG	0 405 233	1/91	Europe				
	FH	1 457 172	9/66	France				

	FI	0 487 014	12/29	Germany			
	FJ	0 511 468	10/30	Germany			
	FK	0 523 437	5/31	Germany			
	FL	44 2569	2/69	Japan			
	FM	55 98152	07/80	Japan			
	FN	94 22807	10/94	WIPO			
	FO	3 532 47	3/91	Japan			
	FP	0 828 231	10/56	Great Britain			
	FQ	50-149668	11/75	Japan			
	FR	55-162772	12/80	Japan			
	FS	60-76072	6/75	Japan			
	FT	51-80862	7/76	Japan			
	FU	50-77375	6/75	Japan			
	FV	55-124763	9/80	Japan			
	FW	0 502 504 A1	9/9/92	Europe			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)		
	FX	Tarzia, G. et al. "Whythesis and anti-inflammatory properties of some pyrrolo(1H,3H)[3,4]pyrimidin-2-ones and pyrrolo(1H,3H)[3,4-d]pyurimidin-2-ones and pyrrolo(1H,3H)-pyrimidin-2-ones. Chemical Abstracts. 27 August 1979, No. 74558p; page 594.
	FY	
	FZ	

Examiner	Date Considered

RJT/lvb
K:\PAT\Bayer\8c1\1449.wpd